Arbutus Biopharma Corporation ABUS Business Segments — G&A

Similar metrics at other companies

UPWKReportable Segment — G&A

$25.56M+11.4%

RSIReportable Segment — G&A

$25.81M+32.0%

QLYSReportable Segment — G&A

$8.5M-5.3%

OUSTReportable Segment — G&A

$16.13M+1.4%

UEReportable Segment — G&A

$9.14M-4.1%

PCVXReportable Segment — G&A

$33.07M+1.3%

Questions, answered.

What is Arbutus Biopharma Corporation's business segments — G&A?

Arbutus Biopharma Corporation (ABUS) reported business segments — G&A of $5.89M in Q1 2026.

How has Arbutus Biopharma Corporation's business segments — G&A changed year-over-year?

Arbutus Biopharma Corporation's business segments — G&A increased by 1.0% year-over-year, from $5.83M to $5.89M.

What is the long-term trend for Arbutus Biopharma Corporation's business segments — G&A?

Over 2 years (2023 to 2025), Arbutus Biopharma Corporation's business segments — G&A has grown at a -15.9% compound annual growth rate (CAGR), from $22.48M to $15.89M.

What does business segments — G&A mean?

This includes the overhead costs associated with managing the business, such as executive compensation, legal fees, and corporate administrative functions. It is a measure of the company's operational efficiency and the scale of its non-research support infrastructure.